- Home
- FONR vs ANL Comparison
FONR vs ANL Comparison
Compare FONR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FONR
- ANL
- Stock Information
- Founded
- FONR 1978
- ANL 2004
- Country
- FONR United States
- ANL Cayman Islands
- Employees
- FONR N/A
- ANL N/A
- Industry
- FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ANL
- Sector
- FONR Health Care
- ANL
- Exchange
- FONR Nasdaq
- ANL Nasdaq
- Market Cap
- FONR 95.7M
- ANL 79.0M
- IPO Year
- FONR 1987
- ANL 2023
- Fundamental
- Price
- FONR $15.22
- ANL $2.05
- Analyst Decision
- FONR
- ANL Strong Buy
- Analyst Count
- FONR 0
- ANL 2
- Target Price
- FONR N/A
- ANL $9.00
- AVG Volume (30 Days)
- FONR 9.4K
- ANL 13.8K
- Earning Date
- FONR 02-12-2025
- ANL 02-24-2025
- Dividend Yield
- FONR N/A
- ANL N/A
- EPS Growth
- FONR N/A
- ANL N/A
- EPS
- FONR 1.42
- ANL N/A
- Revenue
- FONR $102,006,089.00
- ANL $5,000,000.00
- Revenue This Year
- FONR N/A
- ANL N/A
- Revenue Next Year
- FONR N/A
- ANL N/A
- P/E Ratio
- FONR $10.70
- ANL N/A
- Revenue Growth
- FONR 0.70
- ANL N/A
- 52 Week Low
- FONR $14.05
- ANL $1.85
- 52 Week High
- FONR $24.05
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- FONR 47.95
- ANL 44.92
- Support Level
- FONR $15.03
- ANL $2.00
- Resistance Level
- FONR $15.40
- ANL $2.19
- Average True Range (ATR)
- FONR 0.29
- ANL 0.27
- MACD
- FONR 0.03
- ANL -0.01
- Stochastic Oscillator
- FONR 70.41
- ANL 16.81
About FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.